Identifying and monitoring transmission of P. vivax parasites remains a challenge in most countries that have entered the malaria elimination phase.
The goal of this project is to identify and validate serological markers of recent P. vivax infections. Such markers would allow more rapid and accurate evaluation of the impact of control and elimination measures. An added clinical benefit is the potential ability to identify carriers of latent forms of P. vivax parasites that can linger in the liver and cause relapses.
Between 2015 and 2017, FIND coordinated the activities of several partners who profiled the immune responses of a large panel of P. vivax malaria patients from Papua New Guinea, Brazil and Thailand. This permitted the identification and validation of markers of recent infection, which enabled the development of serological tests for P. vivax malaria. FIND also led a consensus-based process to develop target product profiles for diagnostic tests that will use these new biomarkers, and will conduct a technology landscape assessment as well as a market analysis on the use of such tests.